Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11284784 | 0.82 | ALDH1A1 (0.32) | — | |
| SCHEMBL21615221 | 0.79 | HTR1A (0.33) | — | |
| SCHEMBL7778101 | 0.78 | BCHE (0.33) | ADH1BADH1CADH1A | |
| SCHEMBL19908752 | 0.78 | MMP8 (0.31) | — | |
| SCHEMBL23223389 | 0.77 | TSHR (0.30) | — | |
| SCHEMBL7117040 | 0.76 | PKM (0.33) | — | |
| SCHEMBL21870637 | 0.76 | — | — | |
| SCHEMBL20058055 | 0.76 | CYP2D6 (0.32) | — | |
| SCHEMBL18404497 | 0.76 | — | — | |
| SCHEMBL29320305 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208611-B2 | Lubricating oil additives | INFINEUM INTERNATIONAL LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-20200369976-A1 | Lubricating Oil Additives | INFINEUM INTERNATIONAL LIMITED (GB) | 2020-11-26 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | ADH1B 1053/4885ADH1C 1360/4885ADH1A 1409/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | ADH1B 1053/4885ADH1C 1360/4885ADH1A 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.